source
- Novo to pay up to $2.6 billion for rights to Hengrui’s experimental weekly obesity pillNovo Pharmaceuticals has signed a licensing agreement with China's Hengrui Pharma to acquire an experimental oral weight‑loss drug that is administered once a week. Under the deal, Novo could pay…
- Midterm elections could reshape drug pricing, Medicaid funding and research support, industry leaders warnThe November midterm elections are set to influence major health-care policy debates in Washington, according to STAT+. Industry leaders say the outcome could affect Medicaid funding levels, the p…